Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Cabazitaxel in High Risk Operable Prostate Cancer
NCT04622761Phase 2Not yet recruiting
- Start
- Jan 2021
- Primary completion
- Nov 2025
- Modality
- Lipid-based Nanoparticles, Small Molecules
01
Overview
Phase 2, randomised, open-label trial of cabazitaxel ginsenoside liposome injection in prostate cancer (PCa) (2 arms). Primary endpoint: Reduction in treatment failure at 3 years. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
cabazitaxel ginsenoside liposome injection
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04622761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04622761.